Grape King Bio Ltd.

As of June 30, 2026, Grape King Bio Ltd. carries a market capitalization of 13.64B, placing it among publicly traded companies globally. Its enterprise value stands at 11.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Grape King Bio Ltd.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Grape King Bio Ltd. has 148.14M shares outstanding.

As of June 30, 2026, Grape King Bio Ltd. trades at a trailing price-to-earnings ratio of 11.88. The price-to-sales ratio is 1.35, and the price-to-book ratio stands at 1.33.

As of June 30, 2026, Grape King Bio Ltd. trades at an EV/EBITDA multiple of 4.42 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.65 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Grape King Bio Ltd. trades at an EV/FCF ratio of 7.76, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 11.49B versus a market cap of 13.64B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Grape King Bio Ltd. maintains a current ratio of 1.59, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.61, indicating elevated leverage, while an interest coverage ratio of 555.06 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Grape King Bio Ltd. posted a return on equity (ROE) of 11.45, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.73 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.68, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.56, useful for judging operating efficiency across full business cycles. The company generates approximately 14.14M in revenue per employee across its workforce of 716.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.31 indicates how many times Grape King Bio Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Grape King Bio Ltd. recorded 417.67M in income tax expense. That works out to an effective tax rate of 19.08, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.19B, leaving 1.15B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Grape King Bio Ltd.'s stock has declined approximately 31.57% over the past 52 weeks. The 50-day moving average sits at 88.08, while the 200-day moving average is 105.04.

Over the twelve months ended June 30, 2026, Grape King Bio Ltd. generated 10.12B in revenue and converted that into 1.15B in net income, yielding earnings per share of 11.88. EBITDA reached 2.60B, while operating income came in at 2.04B.

As of June 30, 2026, Grape King Bio Ltd. holds 3.70B in cash and equivalents against 186.69M in total debt, resulting in a net debt position of -3.54B. Total book value stands at 10.24B, with working capital of 1.86B providing operational flexibility.

Grape King Bio Ltd. produced 1.99B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -514.12M in capital expenditures, free cash flow totaled 1.48B - equivalent to 9.98 per share.

Over the twelve months ended June 30, 2026, Grape King Bio Ltd. posted a gross margin of 73.47, reflecting its pricing power and cost economics. The operating margin of 20.11 and net profit margin of 11.34 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Grape King Bio Ltd. paid dividends of 6.40 per share. The dividend payout ratio of 39.59 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 10.76, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 11.75, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Grape King Bio Ltd. shareholders.

Grape King Bio Ltd.'s most recent stock split took place on September 15, 2005 with a 439:448 split ratio.

As of June 30, 2026, Grape King Bio Ltd. has an Altman Z-Score of 4.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.